Opaleye Management Inc. Buys Protara Therapeutics Inc, Eton Pharmaceuticals Inc, Kala Pharmaceuticals Inc, Sells Epizyme Inc, Turning Point Therapeutics Inc, Audentes Therapeutics Inc

• New Purchases: TARA, ETON, KALA, MTEM, MYOV, CPRX, VSTM, NERV, CDTX, KALV, PRVB, SELB,
• Added Positions: CRNX, MGNX, EDAP, KDMN, XOMA, NLTX, ODT,
• Reduced Positions: ACAD, FTSV, AMRN, FLXN, ZYME, STXS, TGTX, APTO, MGTA, DCPH,
• Sold Out: EPZM, TPTX, BOLD, ITCI, AXGN, PTCT, BHVN, BPMC, RARX, ACHN, AQST, QTRX, RYTM, FENC, PRTO,

For the details of Opaleye Management Inc.'s stock buys and sells, go to https://www.gurufocus.com/guru/opaleye+management+inc./current-portfolio/portfolio

1. Protara Therapeutics Inc (TARA) - 2,208,472 shares, 14.11% of the total portfolio. New Position
2. Forty Seven Inc (FTSV) - 385,500 shares, 9.96% of the total portfolio. Shares reduced by 31.41%
3. Ocular Therapeutix Inc (OCUL) - 5,122,500 shares, 6.86% of the total portfolio. Shares added by 0.29%
4. Aptose Biosciences Inc (APTO) - 4,022,000 shares, 6.47% of the total portfolio. Shares reduced by 1.54%
5. Neoleukin Therapeutics Inc (NLTX) - 1,400,000 shares, 4.31% of the total portfolio. Shares added by 1.35%

Opaleye Management Inc. initiated holding in Protara Therapeutics Inc. The purchase prices were between $21.02 and $39, with an estimated average price of $29.85. The stock is now traded at around $29.91. The impact to a portfolio due to this purchase was 14.11%. The holding were 2,208,472 shares as of .

Opaleye Management Inc. initiated holding in Eton Pharmaceuticals Inc. The purchase prices were between $2.87 and $7.47, with an estimated average price of $5.9. The stock is now traded at around $5.77. The impact to a portfolio due to this purchase was 4.04%. The holding were 3,640,000 shares as of .

Opaleye Management Inc. initiated holding in Kala Pharmaceuticals Inc. The purchase prices were between $3.69 and $8.79, with an estimated average price of $6.36. The stock is now traded at around $11.86. The impact to a portfolio due to this purchase was 1.96%. The holding were 782,000 shares as of .

Opaleye Management Inc. initiated holding in Molecular Templates Inc. The purchase prices were between $11.31 and $18.26, with an estimated average price of $14.57. The stock is now traded at around $15.76. The impact to a portfolio due to this purchase was 1.92%. The holding were 533,400 shares as of .

Opaleye Management Inc. initiated holding in Myovant Sciences Ltd. The purchase prices were between $6.55 and $15.52, with an estimated average price of $11.33. The stock is now traded at around $19.90. The impact to a portfolio due to this purchase was 1.34%. The holding were 656,000 shares as of .

Opaleye Management Inc. initiated holding in Catalyst Pharmaceuticals Inc. The purchase prices were between $2.61 and $5.21, with an estimated average price of $4.11. The stock is now traded at around $4.70. The impact to a portfolio due to this purchase was 1.09%. The holding were 1,050,000 shares as of .

Opaleye Management Inc. added to a holding in Crinetics Pharmaceuticals Inc by 38.58%. The purchase prices were between $11.52 and $26.46, with an estimated average price of $20.65. The stock is now traded at around $19.21. The impact to a portfolio due to this purchase was 0.41%. The holding were 368,750 shares as of .

Opaleye Management Inc. added to a holding in Macrogenics Inc by 110.62%. The purchase prices were between $4.28 and $12.11, with an estimated average price of $9.16. The stock is now traded at around $28.52. The impact to a portfolio due to this purchase was 0.35%. The holding were 422,300 shares as of .

Opaleye Management Inc. added to a holding in Edap TMS SA by 22.89%. The purchase prices were between $1.72 and $4.47, with an estimated average price of $3.55. The stock is now traded at around $2.74. The impact to a portfolio due to this purchase was 0.25%. The holding were 2,193,500 shares as of .

Opaleye Management Inc. added to a holding in Kadmon Holdings Inc by 22.53%. The purchase prices were between $2.44 and $5.16, with an estimated average price of $4.32. The stock is now traded at around $5.23. The impact to a portfolio due to this purchase was 0.24%. The holding were 1,152,250 shares as of .

Opaleye Management Inc. sold out a holding in Epizyme Inc. The sale prices were between $14.83 and $26.72, with an estimated average price of $21.65.

Opaleye Management Inc. sold out a holding in Turning Point Therapeutics Inc. The sale prices were between $32.02 and $66.17, with an estimated average price of $53.48.

Opaleye Management Inc. sold out a holding in Audentes Therapeutics Inc. The sale prices were between $59.83 and $60, with an estimated average price of $59.94.

Opaleye Management Inc. sold out a holding in Intra-Cellular Therapies Inc. The sale prices were between $12.31 and $34.31, with an estimated average price of $22.

Opaleye Management Inc. sold out a holding in Axogen Inc. The sale prices were between $8.38 and $17.89, with an estimated average price of $12.85.

Opaleye Management Inc. sold out a holding in PTC Therapeutics Inc. The sale prices were between $32.37 and $59.36, with an estimated average price of $50.48.

Opaleye Management Inc. reduced to a holding in ACADIA Pharmaceuticals Inc by 99.27%. The sale prices were between $31.65 and $46.87, with an estimated average price of $41.34. The stock is now traded at around $52.73. The impact to a portfolio due to this sale was -1.8%. Opaleye Management Inc. still held 1,500 shares as of .

Opaleye Management Inc. reduced to a holding in Forty Seven Inc by 31.41%. The sale prices were between $35.28 and $95.42, with an estimated average price of $59.7. The stock is now traded at around $95.51. The impact to a portfolio due to this sale was -1.43%. Opaleye Management Inc. still held 385,500 shares as of .

Opaleye Management Inc. reduced to a holding in Amarin Corp PLC by 31.58%. The sale prices were between $4 and $21.53, with an estimated average price of $16.75. The stock is now traded at around $7.14. The impact to a portfolio due to this sale was -0.93%. Opaleye Management Inc. still held 455,000 shares as of .

Opaleye Management Inc. reduced to a holding in Flexion Therapeutics Inc by 32.23%. The sale prices were between $5.53 and $21.13, with an estimated average price of $15.21. The stock is now traded at around $13.11. The impact to a portfolio due to this sale was -0.57%. Opaleye Management Inc. still held 281,600 shares as of .

Opaleye Management Inc. reduced to a holding in Zymeworks Inc by 24%. The sale prices were between $24.28 and $49.8, with an estimated average price of $41.23. The stock is now traded at around $40.00. The impact to a portfolio due to this sale was -0.39%. Opaleye Management Inc. still held 133,000 shares as of .